Hypertrophic cardiomyopathy (HCM) was the most common myocardial disease, affecting 0.2–0.5% of the population worldwide 1. Up to 30% to 40% HCM patients would experience adverse outcomes 2. Left ...
Hypertrophic cardiomyopathies (HCM) result from distinct single-point mutations in sarcomeric proteins that lead to muscle hypercontractility. While different models account for a pathological ...
We independently select all products and services. While we earn a commission from partner links, commissions do not affect our editors' opinions or evaluations. Learn More. Human capital management ...
For the first time, a medication has impacted heart muscle thickness and function for patients with the most common inherited heart condition, hypertrophic cardiomyopathy, rather than simply ...
SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and ...
Clinical Trials Arena on MSN
Edgewise reports positive top-line results from Phase II CIRRUS-HCM trial
In Part D, designed to support Phase III, dosing was determined by LVOT-G for oHCM and NT-proBNP for nHCM.
Shortness of breath, especially during activities that increase the heart rate, can be an early indicator of HCM. Chest pain, which often feels like tightness or pressure, may arise during physical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results